In a first-of-its-kind development, the Federal Trade Commission has filed a lawsuit against a drug maker for abusing the citizen’s petition process in order to thwart generic competition to a best-selling medicine.

In the complaint, the agency charged that ViroPharma, which is now owned by Shire, “inundated” the Food and Drug Administration with dozens — 46, to be exact — regulatory and court filings to delay the approval of generic Vancocin capsules. The antibiotic is used to treat intestinal infections caused by C. difficile, which causes watery or bloody diarrhea.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy